The validation of the association between elevated PD‐L1 expression and male patients holds significant clinical relevance, as multiple phase III studies investigating first‐line immune checkpoint inhibitors in advanced NSCLC have demonstrated that anti‐PD‐1/anti‐PD‐L1 monotherapy exhibits greater efficacy in men compared to women.50 Here, CD274 is linked to non-small cell lung carcinoma.